Moving forward, a phase Ia/b trial evaluating the combination of crizotinib with an alternative MEK1/2 inhibitor binimetinib in RAS mutant CRC patients with aberrant c-MET was completed. This evidence concerns the gene MET and colorectal carcinoma.